אודות פרק זה
In this episode of Beyond Longevity, Daphna speaks with Dr Peter Scriven, Co-Founder and Clinical & Scientific Director of LONGEVITY, about what longevity medicine should actually look like: moving from reactive, disease-led healthcare towards preventative, personalised medicine that tracks biomarkers, cardiovascular risk and health trajectory over time.
Dr Peter describes much of conventional healthcare as ‘failure-based medicine’ — a system designed to respond once something has gone wrong. He questions the reliance on population-based ‘normal’ laboratory ranges, which can obscure meaningful changes within an individual, and makes the case for longitudinal ‘human telemetry’: following biomarkers and other health data over time rather than relying on isolated snapshots.
They discuss what responsible longevity testing should look like, including a core panel of around 50–80 blood biomarkers, more targeted diagnostics according to age, sex, symptoms and individual goals, and the importance of having a clear clinical reason for every test. Dr Peter also explains why more testing is not necessarily better, and why interpretation, clinical oversight and sensible testing intervals matter.
The conversation examines the realities of longevity medicine and preventative health screening, from several hundred pounds for more focused assessments to several thousand when extensive diagnostics and medical imaging are included, and where he believes people should prioritise their spending.
Dr Peter explains how his father’s missed cardiovascular risk and inadequate lipid testing helped shape his approach to preventative medicine. He also discusses the largely unregulated ‘Wild West’ of longevity, including peptides and other interventions promoted ahead of strong clinical evidence, and the checks patients can make when assessing a longevity clinic or practitioner.
And beneath the diagnostics, biological-age testing and emerging technologies, he returns to the foundations of healthspan: movement, nutrition, sleep and purpose.
For those working with a limited budget, he identifies three areas he believes are worth considering first: a proper cardiovascular risk assessment, omega-3 to omega-6 balance, and GlycanAge testing.
https://longevityclinics.life/
https://www.linkedin.com/in/drpscriven/
00:00 Why Prevention Matters
03:12 Failure-Based Medicine
04:34 Human Telemetry Monitoring
06:28 Testing Without Overtesting
09:53 Core vs Targeted Panels
13:13 Cost and ROI of Diagnostics
17:54 Healthspan Intervention Pyramid
20:53 Normal Ranges vs Trajectories
24:36 Missed Risks Real Stories
28:46 Breaking Medical Silos
33:49 Renaissance Medic Mindset
36:05 Training Beyond Silos
36:49 Regulating Longevity Medicine
37:43 Patients or Permanent Clients
41:01 Too Much Testing Ethics
44:08 Peptides and Amateur Hype
45:42 How to Vet a Clinic
49:01 Budget Biomarkers That Matter
52:13 Foundations and Wearables
55:19 Future of Cellular Medicine
58:30 Long-Term Clinic Journey
01:00:00 Rapid Fire and Wrap Up
